Literature DB >> 8328533

Composite grafting for eyelid reconstruction.

M S Werner1, J J Olson, A M Putterman.   

Abstract

Viable composite grafting is a technique used in eyelid reconstruction in which the graft is obtained from the contralateral eyelid. We reviewed the charts of 51 patients who underwent composite grafting of the eyelid since 1983. The average horizontal length of the defect repaired with this technique was 17.3 mm, and the most common indication for its use was basal cell carcinoma. Postoperatively, 39 (91%) of the 43 patients with available measurements had within 2.0 mm of palpebral fissure symmetry. Furthermore, this method of reconstruction allows survival of the eyelid margin and eyelid margin cilia. Composite grafting of the eyelid is a valuable method for eyelid reconstruction that provides acceptable cosmetic results.

Entities:  

Mesh:

Year:  1993        PMID: 8328533     DOI: 10.1016/s0002-9394(14)71737-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

Review 1.  Congenital upper eyelid coloboma: embryologic, nomenclatorial, nosologic, etiologic, pathogenetic, epidemiologic, clinical, and management perspectives.

Authors:  Hatem A Tawfik; Mohamed H Abdulhafez; Yousef A Fouad
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Jan-Feb       Impact factor: 1.746

2.  Total or subtotal replacement of tarsal plate by novel silicone plate for upper eyelid reconstruction in malignant tumors.

Authors:  Salil Kumar Mandal; Basupurna Majumdar; Purban Ganguly; Stephen C Dryden; James C Fleming; Brian T Fowler
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

3.  Management of the large upper eyelid defects with cutler-beard flap.

Authors:  Duman Rahmi; Balcı Mehmet; Başkan Ceyda; Ozdoğan Sibel
Journal:  J Ophthalmol       Date:  2014-03-17       Impact factor: 1.909

4.  Repair of 50-75% full-thickness lower eyelid defects: Lateral stabilization as a guiding principle.

Authors:  C Blake Perry; Richard C Allen
Journal:  Indian J Ophthalmol       Date:  2016-08       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.